Hogan Lovells is advising Novartis, a global pharmaceutical company, in a definitive agreement for the acquisition of Encore Vision, Inc. for an undisclosed amount.
Encore Vision is a privately-held company based in Fort Worth, Texas, that focuses on the development of a novel treatment in presbyopia. Presbyopia is a common age-related loss of near distance vision characterized by a progressive inability to focus on objects nearby. This acquisition would add a disease modifying topical treatment for presbyopia to the Novartis ophthalmology pipeline.